MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.

Institutional investors and analysts are invited to register to attend the in-person session, which will feature a comprehensive overview of Telix’s therapeutic and precision medicine pipeline, as well as key scientific, clinical and strategic developments across the portfolio.

Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer, Dr. David N. Cade; CEO Therapeutics, Richard Valeix; CEO Precision Medicine, Kevin Richardson and Vice President Discovery Sciences, Dr. Michael Wheatcroft. The program will also feature presentations from key opinion leaders who will provide their perspectives on the clinical and scientific opportunities.

Advance registration is required for in-person attendance. Additional event details, including the venue, agenda and presentation materials, will be provided to registered attendees.

To RSVP or inquire about the R&D Day, please contact annie.kasparian@telixpharma.com or charlene.jaw@telixpharma.com.

Capital Markets Day to be hosted in Melbourne on November 4, 2026 – Save the Date

Telix will also host a Capital Markets Day in Melbourne on Wednesday, November 4, 2026. Telix management will provide updates on the Company’s strategy, growth outlook, financial targets and key business priorities. Further details will be provided in a separate announcement.

Note: These events are for qualified institutional investors and analysts.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. 

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

 New cognitive linguistic entropy measurement finds Claude Shannon’s communications paper surpasses both the Turing Machine (1936) and the Turing Test (1950) — LingEQ Engine launched globally August 1

SILICON VALLEY, Calif., Aug. 6, 2026 /PRNewswire/ — A study applying linguistic entropy measurement to 50 landmark AI papers — spanning 1936 to 2025 — has produced a counterintuitive result: the text with the highest measured cognitive density was not written about AI. Claude Shannon’s 1948 A Mathematical Theory of Communication registers the highest LEQ (194, Linguistic Entropy Quotient) value in the entire corpus — surpassing Turing’s 1936 On Computable Numbers (LEQ 193) and Turing’s 1950 Turing Test paper (LEQ 189). GPT-3, AlphaFold, and DeepSeek-R1 cluster between 168 and 170. The 1955 Dartmouth Proposal, which named the field of artificial intelligence, registers the lowest early-period value at 150. Early AI texts created new conceptual objects and theoretical boundaries; recent landmark work, however transformative, builds within established frameworks.

The study, 90 Years Engraved by Entropy: LEQ Analysis of 50 Landmark AI Papers, is the inaugural release of the LingEQ Curation Series. Conducted using the LingEQ Engine, the study uses multiple language models as analytical instruments, calibrated against an anchor corpus to produce reproducible linguistic entropy values. Its measurements are derived entirely from the text itself, independent of authorship, publication venue, or citation history. The theoretical framework is presented in The Scale of Language, forthcoming from Springer Nature.

The research addresses a structural gap in scientific publishing. arXiv now receives over 20,000 preprints each month, while papers can spend one to two years in peer review. AI can generate increasingly polished texts, making originality and reliability harder to assess. Each submission is evaluated by two or three reviewers, introducing sampling bias and the limits of individual expertise. Foundational work may disappear into an unread database, while papers aligned with current trends can accumulate citations despite limited lasting value. Peer review measures consensus, citation counts measure influence – neither measures what a text actually contains.

LingEQ Engine opened for global public beta on August 1, 2026.

About LingEQ Technologies:

LingEQ Technologies (LingEQ.com) is an independent language measurement platform quantifying the cognitive depth of written text in the age of AI, operating across Silicon Valley, Brisbane, Hong Kong, and Shenzhen.

Media contact:
lingeqcs@lingeq.com

WASHINGTON, Aug. 6, 2026 /PRNewswire/ — The Global Environment Facility (GEF) Council today announced the selection of Diego Mesa Puyo as the family of funds’ next CEO and Chairperson. Mesa Puyo, an international leader in energy policy, economic development, and sustainability, and former Minister of Energy and Mines from Colombia, will serve an initial term of four years, aligned with the GEF-9 funding period and the last sprint towards critical 2030 environmental goals.

Before his selection as the GEF’s next CEO and Chairperson, Mesa Puyo served as Deputy Chief of the Climate Policy Division of the International Monetary Fund. As Colombia’s Minister of Energy and Mines in the 2018-2022 administration, he led one of Latin America’s most ambitious energy transition agendas, launching market reforms that mobilized more than $3 billion in private investment and accelerated the deployment of variable renewable energy from near-zero levels to one of the fastest-growing clean energy markets in the region. He also played a central role in advancing energy transition and climate action legislation, embedding sustainability objectives in economic and development policy.

“I am deeply honored to serve as the next CEO and Chairperson of the Global Environment Facility at this pivotal moment for the international community,” Mesa Puyo said. “Countries need trusted partners that can help turn ambition into action. Building on the GEF’s remarkable legacy, I look forward to working with the Secretariat, member countries, and partners around the world to achieve environmental and development goals together by integrating solutions, catalyzing investment, and delivering measurable results for people and planet.”

The GEF is the world’s largest public funder for the environment and serves international conventions on biodiversity, climate change, and pollution. Donor countries have pledged an initial $3.9 billion for an ambitious ninth replenishment of the GEF Trust Fund, reflecting a strong commitment to protect and restore nature through multilateral cooperation.

The Global Environment Facility is the world’s family of funds for the environment. As the financial mechanism for six multilateral conventions, it supports countries’ efforts to tackle the root causes of environmental degradation — advancing global goals for nature, climate, and pollution. Over the past three decades, the GEF has been the largest public funder for the environment and provided more than $27 billion in financing, primarily as grants, and mobilized another $155 billion for country-driven priority projects.

Read the full press release here in English, Spanish, and French.

• Lisa Beaudoin appointed Chief Product Officer, leading a newly unified product development organization across DXC
• Beaudoin most recently led the development and launch of DXC OASIS, the company’s AI-powered orchestration platform for managed services, now in production with 57 customers
• Appointment follows the recent naming of Paul Taylor as President, Dan Gray as President, Global Infrastructure Services and Holly Grant as President, AI Innovation and Strategy & LabX, further strengthening DXC’s leadership team and operating model

ASHBURN, Va., Aug. 6, 2026 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced the appointment of Lisa Beaudoin as Chief Product Officer. In this role, Beaudoin will lead a newly unified product development organization spanning DXC’s portfolio, with responsibility for product strategy, engineering, lifecycle management, and market execution. Her appointment reflects DXC’s focus on scaling AI-centric leadership and product-led innovation across the company and accelerating the delivery of differentiated offerings for customers. DXC also recently appointed Paul Taylor as President, Dan Gray as President, Global Infrastructure Services (GIS), and Holly Grant as President, AI Innovation and Strategy & LabX. She will report to Paul Taylor, President, effective immediately.

Beaudoin previously served as Vice President, Platform Innovation and Automation, where she led the product strategy and engineering of AI-driven enterprise platforms. Working across product, engineering, operations, and customer teams, she has overseen the full product lifecycle, from strategic positioning and development through market execution, with a focus on improving user experience, operational performance, and measurable business value for customers.

Most recently, Beaudoin co-led the development and launch of DXC OASIS alongside Dan Gray, President of GIS, helping bring together product strategy, technical innovation, and customer insight to take the company’s AI platform from concept to production in just over a year. The platform is now in production with 57 customers and serves as the foundation for a growing set of scalable, AI-enabled solutions that deliver measurable business value while transforming managed services for mission-critical enterprises at scale.

“This is a natural next step in the evolution of DXC,” said Raul Fernandez, Chief Executive Officer, DXC Technology. “We are simplifying how we operate, consolidating product development under one proven leader, and creating greater consistency across the way we build and bring products to market. Lisa has demonstrated her ability to turn customer needs into scalable platforms that deliver measurable value, and she will help accelerate how we innovate, execute, and deliver outcomes for our customers.”

In her expanded role, Beaudoin will apply the disciplined product development approach behind DXC OASIS, rooted in deep customer and user insight, across DXC’s broader portfolio. She will bring product teams together under a unified organization, strengthen the connection between customer needs and product development, and accelerate the delivery of scalable offerings that support DXC’s Core and Fast Track strategies. She will also work closely with DXC’s technology and business leaders to ensure product and engineering teams are aligned from the outset and that DXC’s offerings complement one another and fully leverage the company’s strategic partnerships. By bringing product development under a single organization, DXC aims to accelerate innovation, reduce complexity, and bring new capabilities to customers more quickly. 

“Lisa brings the product discipline we need to strengthen execution across DXC,” said Paul Taylor, President, DXC Technology. “Putting our customers at the center of every product decision will help us focus on the opportunities that matter most, connect product, technology and engineering more effectively, and move with greater speed and clarity. By bringing product development together under one leader, we’ll build better solutions, execute with greater consistency, and ensure innovation is always driven by the needs of our customers.”

“DXC has deep industry expertise, strong engineering capabilities, and an unmatched understanding of the complex technology and business environments in which our customers operate,” said Beaudoin. “My focus will be on bringing those strengths together through a more unified product organization that starts with a clear understanding of customer and operator needs, focuses on the highest-value opportunities, and moves with speed. By connecting disciplined product strategy with our strong technology leadership, we can build products that are technically feasible, operationally scalable, work together across our portfolio, and directly tied to the outcomes our customers and partners need.”

Before joining DXC, Beaudoin co-founded Brightspot, an enterprise software company, and held senior product, design, and creative leadership roles at WebMD, AOL, and The Wall Street Journal/Dow Jones. Across these roles, she led the development of digital platforms, publishing tools, and consumer applications for global organizations. She is a graduate of Parsons School of Design.

About DXC Technology

DXC Technology (NYSE: DXC) is a leading enterprise technology and innovation partner delivering software, services, and solutions to global enterprises and public sector organizations — helping them harness AI to drive outcomes at a time of exponential change with speed. With deep expertise in Managed Infrastructure Services, Application Modernization, and Industry-Specific Software Solutions, DXC modernizes, secures, and operates some of the world’s most complex technology estates. Learn more on dxc.com.

Media Contact: Ashley Houk-Temple, DXC Technology, ashley.houktemple@dxc.com

PANAMA CITY, Aug. 5, 2026 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3-AI company, today announced a 2 million USDT trading campaign inviting users to trade some of today’s most active market opportunities across cryptocurrencies, stocks, indices, forex, commodities, and other asset classes.

Running from August 5 to August 31, 2026 (UTC+8), the campaign marks the fifth edition of BingX’s Global Capital Gala series. The campaign encourages users to explore trending opportunities across multiple asset classes through BingX’s unified multi-asset trading platform.

The campaign arrives as narratives, particularly those across the artificial intelligence and memory technology industries, continue to attract market attention, alongside a wave of earnings reports from major global companies. By bringing these opportunities together, BingX enables traders to respond to market-moving events across multiple asset classes as they unfold.

Participants can earn rewards by completing market trend-themed trading tasks throughout the campaign. These include incentives for first-time trading, daily futures trading, reaching cumulative futures trading milestones, and participating in market trend-themed events. Eligible users who complete the applicable requirements will be able to claim trading bonus rewards and share in the total prize pool.

“Markets no longer move in isolation,” said Kevin Lee, Chief Strategy Officer at BingX. “A major earnings report can influence AI stocks, semiconductor companies, cryptocurrencies, commodities, and broader market sentiment within hours. Traders increasingly want one platform where they can quickly access what’s moving, rather than switching between different brokers or exchanges. That’s exactly the experience BingX is building.”

About BingX

Founded in 2018, BingX is a leading crypto exchange and Web3-AI company, serving over 40 million users worldwide. Ranked among the top five global crypto derivatives exchanges and a pioneer of crypto copy trading, BingX addresses the evolving needs of users across all experience levels.

Powered by a comprehensive suite of AI-driven products and services, including futures, spot, copy trading, and TradFi offerings, BingX empowers users with innovative tools designed to enhance performance, confidence, and efficiency.

BingX has been the principal partner of Chelsea FC since 2024, and became the first official crypto exchange partner of Scuderia Ferrari HP in 2026.

For more information, please visit: https://bingx.com/